Schiller J T, Hidesheim A
Laboratory of Cellular Oncology, DBS, Building 36, RM 1D32, Bethesda, MD 20892, USA.
J Clin Virol. 2000 Oct;19(1-2):67-74. doi: 10.1016/s1386-6532(00)00091-3.
the knowledge that sexually transmitted infection with one of a limited number of human papillomaviruses (HPVs) is a central cause of almost all cervical cancers affords the opportunity to prevent this common cancer through anti-viral vaccination.
the spectacular success of vaccines in preventing several other viral diseases offers hope that immunoprophylaxis against the relevant HPVs could lead to a major reduction in cervical cancer incidence.
the results of preclinical studies and early phase clinical trials of virus-like particle (VLP) based subunit vaccines have been very encouraging. However, unique aspects of papillomavirus biology and genital tract infections, and the lack of sexual a transmission model for papillomavirus, make it far from certain that effective prophylactic vaccination against genital HPV infection will be easily achieved. Future clinical efficacy trials will likely test the hypothesis that parenteral injection of VLPs can induce antibody mediated and type specific protection against genital tract HPV infection and subsequent development of premalignant neoplastic disease.
已知感染少数几种人乳头瘤病毒（HPV）中的一种是几乎所有宫颈癌的主要病因，这为通过抗病毒疫苗预防这种常见癌症提供了机会。
疫苗在预防其他几种病毒性疾病方面取得的显著成功让人希望，针对相关HPV的免疫预防能够大幅降低宫颈癌的发病率。
基于病毒样颗粒（VLP）的亚单位疫苗的临床前研究和早期临床试验结果非常令人鼓舞。然而，乳头瘤病毒生物学和生殖道感染的独特方面，以及缺乏乳头瘤病毒的性传播模型，使得能否轻易实现针对生殖道HPV感染的有效预防性疫苗接种还远不能确定。未来的临床疗效试验可能会检验这样一个假设，即通过肠胃外注射VLP能够诱导抗体介导的、针对生殖道HPV感染以及随后癌前肿瘤性疾病发生的型特异性保护作用。
